Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Liraglutide ‘option’ for treating pediatric type 2 diabetes

Publish date:: October 2, 2019

Key clinical point: Liraglutide offers another option for treating children with type 2 diabetes in whom metformin monotherapy fails.

Major finding: The primary endpoint of the trial, which was the mean change in HbA_1c from baseline to 26 weeks, was met, with a greater percentage point decrease with liraglutide than placebo (–0.64 vs. +0.42), with an estimated treatment difference of –1.06 percentage points (P less than .001).

Study details: ELLIPSE was a phase 3, 52-week, randomized, part double-blind, part open trial of 135 children with type 2 diabetes treated with liraglutide or placebo on top of metformin with or without basal insulin.

Disclosures: Novo Nordisk initiated and funded the trial, and most of the investigators reported receiving funds from the company outside the submitted work. Dr Barrett disclosed being a consultant to and/or receiving honoraria from AstraZeneca, Novo Nordisk, and Servier.

Citation:

Barrett T et al. EASD 2019. Abstract 84.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan,